✦ LIBER ✦

The rivastigmine high-dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study

✍ Scribed by Cummings, Jeffrey; Bellelli, Giuseppe; Black, Sandra; Bakchine, Serge; Krahnke, Tillmann; Strohmaier, Christine

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Incidence and predictors of response to

✍ Molinuevo, Jose Luis; Grossberg, George; Frölich, Lutz; Galvin, James; Krahnke, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 150 KB

Predictors of response to the 13.3 and 9

✍ Molinuevo, J.L.; Grossberg, G.; Frölich, L.; Galvin, J.; Krahnke, T.; Strohmaier 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Efficacy of the 13.3 mg/24 h rivastigmin

✍ Black, Sandra; Bakchine, Serge; Bellelli, Giuseppe; Molinuevo, Jose Luis; Downs, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Efficacy, safety and tolerability of riv

✍ Farlow, Martin; Meng, Xiangyi; Rensch, Scott; Somogyi, Monique 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Efficacy, safety and tolerability of riv

✍ Farlow, Martin; Meng, Xiangyi; Somogyi, Monique 📂 Article 📅 2013 🏛 American Psychiatric Publishing Inc 🌐 English ⚖ 61 KB

A 24-week, open-label extension to the A

✍ Farlow, Martin; Grossberg, George; Sadowsky, Carl; Meng, Xiangyi; Somogyi, Moniq 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 51 KB